• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

PROLONG-9FP Clinical Studies

International Trial Shows Clinical Efficacy of rIX-FP for Once Weekly Prophylaxis

Results of Phase I/II PROLONG-9FP trial program also demonstrate efficacy in treatment of bleeding episodes and improved pharmacokinetics of rIX-FP compared to current treatment options; recombinant albumin fusion platform forms basis of innovation.

Learn more

Population Pharmacokinetic Model for rIX-FP Presented at ISTH

Recombinant albumin fusion platform forms basis of innovation.

Learn more

Hemophilia B Treatment in Late-stage Development

CSL Behring is enrolling pediatric patients in a pivotal trial of rIX-FP, recombinant fusion protein linking coagulation factor IX with recombinant albumin.

Learn more

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

PROLONG-9FP

PROLONG-9FP (CSL654_3002) is a pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years).

Information about the study design is available on www.clinicaltrials.gov.

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Study information is available on www.clinicaltrials.gov. (PROLONG-9FP CSL654_3003)

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Information about this Phase II/III recombinant factor study can be found at www.clinicaltrials.gov. (PROLONG CSL654_3001)

Results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B were publicly presented and published in BLOOD 2012 (e-print available) showing that rIX-FP achieved a 91.57 hours mean half-life, incremental recovery of 1.376 (IU/dL) / (IU/kg), and clearance of 0.75 mL/h/kg. This was an extension in half-life of 5.3 times that of the currently available recombinant FIX therapy. The trial was registered at www.clinicaltrials.gov as no. NCT01233440.





Last Updated: 9/12/2014 1:43 PM
  • E-mail
  • Print
  • Share